Molecule News and Research

RSS

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today.

4 Feb 2010

Amantadine binds to and blocks critical M2 proton channel necessary for influenza virus to infect healthy cells

Antiviral drugs block influenza A viruses from reproducing and spreading by attaching to a site within a proton channel necessary for the virus to infect healthy cells, according to a research project led by Iowa State University's Mei Hong and published in the Feb. 4 issue of the journal Nature.

4 Feb 2010

Helicos BioSciences to install Single Molecule and Genetic Analysis Systems at SLI and Stanford University

Helicos BioSciences Corporation today announced the completion of the sale of a Helicos® Single Molecule System to the St. Laurent Institute (SLI). The installation of the system is expected to be completed in early February.

4 Feb 2010

New discovery lays foundation for development of new anti-HIV drugs

A team of scientists at The Scripps Research Institute has identified two compounds that act on novel binding sites for an enzyme used by the human immunodeficiency virus (HIV), the virus that causes AIDS.

4 Feb 2010

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer.

4 Feb 2010

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.

4 Feb 2010

Bionanomotors can be used some day to move and manipulate molecules at nanoscale

A group of Marshall University researchers and their colleagues in Japan are conducting research that may lead to new ways to move or position single molecules-a necessary step if man someday hopes to build molecular machines or other devices capable of working at very small scales.

3 Feb 2010

Pall launches PallSep Biotech filtration system

Pall Corporation, a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.

From Pall Corporation 3 Feb 2010

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

For the first time, researchers from the University of Pennsylvania School of Medicine have found that three different degenerative brain disorders are linked by a toxic form of the same protein. The protein, called Elk-1, was found in clumps of misshaped proteins that are the hallmarks of Parkinson's disease, Alzheimer's disease, and Huntington's disease.

3 Feb 2010

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

The FDA on Monday said it's entering into a collaboration with the nonprofit group PATH "to speed creation of a pneumococcal vaccine for children in developing nations," United Press International reports (2/1).

3 Feb 2010

Research offers new hope for rare metabolic disorder

A research team led by biochemist Scott Garman at the University of Massachusetts Amherst has for the first time determined the mechanism of one of the cell's "recycling" enzymes, human alpha-galactosidase or alpha-GAL, as it breaks down substances in the lysosome, the cell's recycling center.

2 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

Argonaute binds to microRNA and shuts down protein production

Johns Hopkins scientists believe they may have figured out how genetic snippets called microRNAs are able to shut down the production of some proteins.

2 Feb 2010

Unusual molecule in brain and retina can trigger vision loss

Scientists have identified a double agent in the eye that, once triggered, can morph from neuron protector to neuron killer. The discovery has significant health implications since the neurons killed through this process results in vision loss and blindness.

2 Feb 2010

Gene mutation can trigger preterm births, says study

Mutation of a gene that helps protect the body from genetic instability leads to cellular and molecular changes in the pregnant uterus that trigger premature birth, according to a study appearing online Feb. 1 in the Journal of Clinical Investigation.

2 Feb 2010

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

Molecule News and Research

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

Amantadine binds to and blocks critical M2 proton channel necessary for influenza virus to infect healthy cells

Helicos BioSciences to install Single Molecule and Genetic Analysis Systems at SLI and Stanford University

New discovery lays foundation for development of new anti-HIV drugs

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Bionanomotors can be used some day to move and manipulate molecules at nanoscale

Pall launches PallSep Biotech filtration system

Researchers find three different degenerative brain disorders linked by toxic form of Elk-1 protein

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

Research offers new hope for rare metabolic disorder

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Argonaute binds to microRNA and shuts down protein production

Unusual molecule in brain and retina can trigger vision loss

Gene mutation can trigger preterm births, says study

FDA and PATH collaborate to advance pneumococcal vaccine development for children

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News